Volume 25, Number 7—July 2019
CME ACTIVITY - Synopsis
Prescribing Patterns for Treatment of Mycobacterium avium Complex and M. xenopi Pulmonary Disease in Ontario, Canada, 2001–2013
Table 3
Regimen | Specialty, no. (%) patients |
||||
---|---|---|---|---|---|
Respirology, n = 383 (55.7) | ID, n = 69 (10.0) | GIM, n = 51 (7.4) | FP/GP, n = 85 (12.3) | Other/unknown, n = 100 (14.5) | |
Standard triple therapy | 166 (43.3) | 37 (53.6) | 22 (43.1) | 34 (40.0) | 31 (31.0) |
Macrolide monotherapy | 55 (14.4) | 7 (10.1) | <5 (≤9.8) | 14 (16.5) | 15 (15.0) |
Macrolide + rifamycin or fluoroquinolone | 38 (9.9) | ≤5 (≤7.2) | ≤5 (<9.8) | 6 (7.1) | 8 (8.0) |
Other | 124 (32.4) | 20–25 (29.0–36.1) | 20 (39.2) | 31 (36.5) | 46 (46.0) |
*Includes the regimen dispensed for at least the first 60 d of treatment. According to privacy regulations, values representing<6 persons are reported as <5, and data are presented as a range of values for categorical variables where back-calculation is possible. GIM, general internal medicine; FP/GP, family practice/general practice; ID, infectious diseases.
Page created: June 17, 2019
Page updated: June 17, 2019
Page reviewed: June 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.